Werewolf Therapeutics (NASDAQ:HOWL) Shares Up 5.4%

Werewolf Therapeutics, Inc. (NASDAQ:HOWLGet Rating)’s share price shot up 5.4% during mid-day trading on Thursday . The stock traded as high as $4.43 and last traded at $4.09. 50,460 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 237,604 shares. The stock had previously closed at $3.88.

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Werewolf Therapeutics in a research note on Thursday, June 2nd.

The firm has a market capitalization of $114.49 million, a P/E ratio of -0.75 and a beta of -0.14. The business’s 50 day simple moving average is $4.50 and its two-hundred day simple moving average is $6.34.

A number of large investors have recently added to or reduced their stakes in HOWL. Northern Trust Corp grew its stake in shares of Werewolf Therapeutics by 184.2% in the fourth quarter. Northern Trust Corp now owns 200,065 shares of the company’s stock worth $2,383,000 after acquiring an additional 129,661 shares during the period. Geode Capital Management LLC grew its stake in shares of Werewolf Therapeutics by 26.2% in the third quarter. Geode Capital Management LLC now owns 136,472 shares of the company’s stock worth $2,341,000 after acquiring an additional 28,294 shares during the period. Granite Point Capital Management L.P. bought a new stake in shares of Werewolf Therapeutics in the fourth quarter worth approximately $179,000. BlackRock Inc. grew its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 1,283,545 shares of the company’s stock worth $5,647,000 after acquiring an additional 7,337 shares during the period. Finally, State Street Corp grew its stake in shares of Werewolf Therapeutics by 29.1% in the first quarter. State Street Corp now owns 335,087 shares of the company’s stock worth $1,474,000 after acquiring an additional 75,461 shares during the period. Institutional investors and hedge funds own 72.69% of the company’s stock.

About Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Recommended Stories

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.